(Q47548690)

English

Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

scientific article published on 25 January 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Tonya Villafana

6

object named as

Tonya Villafana

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Joseph B Domachowske

1

object named as

Joseph B Domachowske

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

author name string

Anis A Khan

2

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Mark T Esser

3

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Kathryn Jensen

4

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Therese Takas

5

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Filip Dubovsky

7

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

M Pamela Griffin

8

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

publication date

25 January 2018

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Pediatric Infectious Disease Journal

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Etiology of severe pneumonia in Ecuadorian children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

The burgeoning burden of respiratory syncytial virus among children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

The burden of respiratory syncytial virus infection in young children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Influenza- and respiratory syncytial virus-associated mortality and hospitalisations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Diagnosis and management of bronchiolitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Incidence of respiratory syncytial virus-positive hospitalizations in Germany.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Respiratory syncytial virus and parainfluenza virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6133204

2 November 2018

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/29373476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/INF.0000000000001916

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 February 2018

http://europepmc.org/abstract/MED/29373476

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47548690&oldid=2158561678"